Fengyuan Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for paramivir injections approved and issued by the State Drug Administration. The registration classification is 3 types of chemicals, with a specification of 60 ml: 0.3 g. The indication is to treat influenza A or B, and the drug approval number is valid until October 12, 2031. Obtaining this certificate will enrich the company's product line, optimize the product structure, and enhance market competitiveness. Pharmaceutical production and sales are uncertain due to factors such as industry policies and market environment. Investors are kindly requested to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.